Lantern Pharma| How AI Agents Are Harmonizing to Conquer Rare Cancers and Power Oncology Drug Development
In this LinkedIn article, Panna Sharma outlines how multi‑agent AI systems like withZeta are being developed to transform oncology drug discovery by enabling specialized AI “agents” to autonomously collaborate on complex tasks such as literature synthesis, biomarker analysis, and clinical strategy, accelerating research on rare cancers. The piece highlights the urgent need for speed and precision in rare cancer research and argues that orchestrated AI intelligence could drastically shorten discovery timelines while improving the quality of insights driving therapeutic development. 
Lantern Pharma| How AI Agents Are Harmonizing to Conquer Rare Cancers and Power Oncology Drug Development